Regard Raises $61M in Series B Funding

Regard Raises $61M in Series B Funding

Liora Chen
3 min read

Regard Secures $61M in Series B Funding, Valued at $350M

Regard, a digital health startup, has successfully raised $61 million in a Series B funding round, significantly boosting its valuation to a noteworthy $350 million. The round was expertly led by Oak HC/FT and also saw active participation from Cedars-Sinai Health Ventures and existing investors. Since its establishment in 2017, Regard has harnessed the power of AI to meticulously analyze patient health data, empowering physicians to streamline their processes, consequently leading to enhancements in diagnosing accuracy. This innovative approach by Regard has allowed doctors to seamlessly detect various health conditions, with a notable case where a general physician utilized Regard to identify atrial fibrillation, a potential oversight by a cardiologist.

Aside from the direct benefits to healthcare professionals, which include saving time and delivering accurate diagnostic outcomes, Regard's software solutions have also been found to create new billing opportunities for hospital financial administrators based on the identification of previously undetected conditions. The company has shown substantial growth, experiencing a remarkable revenue surge of 4.5 times in 2023, with projections pointing towards similar growth in the current year. Notably, Regard anticipates achieving profitability within the next two years, a testament to its steadfast trajectory within the healthcare technology landscape.

Investors are notably enthusiastic about the measurable impact on physician productivity, the reduction of burnout, accurate coding, and positive clinical outcomes. Since its inception in 2021, Regard has solidified partnerships with prominent healthcare systems such as Banner Health, Sentara Healthcare, Montefiore Medical Center, and Cedars-Sinai Medical Center. Competitors in this space include Engage One by 3M and the startup Pieces. Furthermore, Nancy Brown of Oak HC/FT has reiterated the firm's confidence in Regard's leadership position, praising its scalability and robust return on investment for clients.

Key Takeaways

  • Regard secures $61 million in Series B funding, elevating its valuation to $350 million.
  • AI-driven software empowers physicians to detect health conditions with heightened accuracy and efficiency.
  • Regard's technology has notably caught previously overlooked conditions, leading to significant shifts in patient treatment.
  • The startup has witnessed a remarkable revenue growth of 4.5 times in 2023 and is on track to achieve profitability within two years.
  • Investors commend Regard for its positive impact on physician productivity and clinical outcomes.


The $61 million Series B funding obtained by Regard serves as an affirmation of its dominance within the market, capturing the attention of influential investors such as Oak HC/FT and Cedars-Sinai Health Ventures. The impactful utilization of AI-driven diagnostics by Regard not only enhances physician efficiency but also paves the way for potential transformations in healthcare billing and treatment protocols. In the short term, Regard's surge towards profitability stands to benefit investors and key partners like Banner Health. On a longer-term horizon, the technological advancements made by Regard could potentially redefine medical data analysis, influencing industry benchmarks while simultaneously affecting its competitors.

Did You Know?

- **Series B Funding**:
  - This stage in the venture capital funding process necessitates that companies have already validated their business model and are now seeking expansion. Typically, this round involves larger investments from a broader array of investors, including venture capital firms, private equity firms, and strategic partners.

- **Atrial Fibrillation**:
  - Atrial fibrillation (AFib), characterized by an irregular heartbeat, can lead to severe complications such as blood clots, stroke, heart failure, and other heart-related issues. Timely detection and intervention are pivotal in managing AFib and preventing potentially life-threatening health complications.

- **Oak HC/FT**:
  - Known for its specialization in healthcare and financial technology investments, Oak HC/FT is a venture capital firm that offers growth and early-stage funding to companies in these sectors. Their focus on innovative solutions aims to drive significant change and value within the industries they operate.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings